4. The variant IgG of claim 1 which has a higher binding affinity for FcRn at pH 6.0 than at pH 7.4.

5. The variant IgG of claim 1 which has an equal or higher efficacy than the IgG having the wild-type human IgG1 Fc region.

6. The variant IgG of claim 5 which has a higher efficacy than the IgG having the wild- type human IgG1 Fc region.

7. The variant IgG of claim 1 which is a human or humanized IgG.

8. The variant IgG of claim 1, wherein the variant IgG is an anti-VEGF antibody.

9. The variant IgG of claim 1, wherein the variant IgG is a variant of bevacizumab.

10. The variant IgG of claim 1 comprising the heavy chain variable domain comprising SEQ ID NO:1 and the light chain variable domain comprising SEQ ID NO:2.

11. A pharmaceutical composition comprising the variant IgG of claim 1 and a pharmaceutically acceptable carrier.

12. A kit comprising the variant IgG of claim 1, in a container, and instructions for use.

13. A variant IgG1 comprising a human IgG1 Fc region comprising amino acid substitutions relative to a wild-type human IgG1 Fc region at amino acid residues 308 and 434, numbered according to the EU index as in Kabat, wherein the variant IgG1 has an increased half- life compared to the half- life of an IgG1 having the wild- type human IgG1 Fc region, and wherein the amino acid substitution at amino acid residue 308 is a substitution with proline, and the amino acid substitution at amino acid residue 434 is a substitution with alanine.

14. Use of a variant IgG of claim 8 in the manufacture of a medicament for treating tumor in a subject.

15. Use of a variant IgG of claim 8 in the manufacture of a medicament for treating a disease or condition in a subject where VEGF activity is angiogenesis.

16. Use of a variant IgG of claim 8 in the manufacture of a medicament for inhibiting or preventing growth of cancer cells in a subject.

17. The use of claim 14, 15, or 16, wherein the variant IgG is to be administered to the subject every 4 weeks or longer.